Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.260 enrolled

Overview

To evaluate efficacy of tolterodine extended release formulation compared with immediate release formulation in subjects with symptoms of overactive bladder

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

260

Conditions

Urinary Incontinence

Interventions

tolterodine extended release capsuleDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with a diagnosis of overactive bladder. Exclusion Criteria: * Subjects with significant stress incontinence as determined by the investigator. * Subjects with recurrent urinary tract infections defined as treated for UTI; 5 times in the last year.

Locations (7)

Pfizer Investigational Site

Beijing, Beijing Municipality, China

Pfizer Investigational Site

Beijing, Beijing Municipality, China

Pfizer Investigational Site

Huangzhou, Zhejiang, China

Pfizer Investigational Site

Beijing, China

Outcomes

Primary Outcomes

To evaluate the efficacy of tolterodine extended release formulation compared with immediate release formulation after 8 weeks of treatment in subjects with symptoms of overactive bladder

Secondary Outcomes

To evaluate the safety of tolterodine extended release formulation compared with immediate release formulation after 8 weeks of treatment in subjects with symptoms of overactive bladder.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.